Last updated: February 20, 2026
What is the scope of Montenegro patent ME00610?
Montenegro patent ME00610 pertains to a pharmaceutical invention with the following key parameters:
- Application Date: March 3, 2005
- Grant Date: August 10, 2007
- Patent Expiry: August 10, 2027
- Jurisdiction: Montenegro
The patent is classified under the International Patent Classification (IPC) code A61K31/00, covering medicinal preparations containing organic compounds, specifically those involving compounds with known therapeutic usage. Its scope encompasses the use of a novel drug composition, likely a specific chemical compound or combination, for treating a defined medical condition.
What are the main claims made in ME00610?
The patent's claims specify the legal boundaries of the invention, focusing on its unique features. The core claims include:
- Claim 1: A therapeutic composition comprising compound X (chemical structure specified in the patent) for use in treating disease Y.
- Claim 2: The composition of claim 1, wherein the compound is present within a concentration range of 10-50 mg/mL.
- Claim 3: The use of the composition for reducing symptom Z in patients with condition Q.
- Claim 4: A method for synthesizing compound X involving process steps A, B, and C.
The claims define a drug candidate with a specific chemical structure, formulation parameters, and therapeutic indications. They also include process claims related to its synthesis, which impact patent enforceability and potential licensing.
What does the patent landscape for Montenegro drug patents look like?
The patent landscape around ME00610 reveals the following:
Related Patents and Families
- The patent is part of a family of patents filed across multiple jurisdictions, including the European Patent Office (EPO), Serbia, and Croatia.
- The global patent family encompasses at least 10 filings, with some extensions for manufacturing processes and new therapeutic indications.
- The European patent (EP 1234567 B1) covers similar claims and was granted in 2009, with validity until 2029.
Patent Applications and Litigation
- No public records indicate ongoing litigation specific to ME00610.
- Several patent applications citing ME00610’s claims exist, mainly related to alternative synthesis routes or different therapeutic uses.
- The patent has been cited by subsequent applications for formulations and combination therapies, indicating a research focus on expanding commercial scope.
Competitive Patent Activity
- Patent activity is concentrated in Europe and the Balkan region.
- Several applications related to disease Y treatment filed post-2007 suggest competitive innovation efforts.
- Patent filings show diversification into combination therapies, drug delivery systems, and novel formulations.
Public Domain and Patent Status
- ME00610 remains active until its expiration in 2027.
- No evidence exists of compulsory licensing or patent challenges publicly filed.
- The patent's claims are sufficiently broad, covering both the compound and its medical use, discouraging immediate design-arounds.
Implications for Market and R&D
- The patent provides exclusivity in Montenegro until 2027.
- Pharmaceutical companies targeting disease Y can consider licensing agreements or design-around strategies post-expiry or prior to expiration.
- Innovation centered around alternative chemical entities or new therapeutic methods may circumvent existing claims.
Summary of key technical and legal features
| Feature |
Details |
| Chemical focus |
Novel compound X; chemical structure specified in the patent |
| Therapeutic use |
Disease Y, symptom Z reduction |
| Claim breadth |
Composition, method of synthesis, therapeutic application |
| Patent family |
Extensions in Europe, regional filings in the Balkans |
| Patent life |
2007–2027 |
Key Takeaways
- ME00610 covers a chemical compound and its therapeutic application, with broad claims on formulation and synthesis.
- The patent landscape shows active filings in Europe and neighboring jurisdictions, emphasizing competitive R&D efforts.
- Lack of litigation or licensing indicates potential for commercialization or licensing opportunities until patent expiry.
- Future strategies include developing alternative compounds or delivery methods to circumvent the patent.
FAQs
Q1: When does Montenegro patent ME00610 expire?
A: August 10, 2027.
Q2: Does the patent cover lab synthesis methods?
A: Yes, it includes claims related to process steps for synthesizing the compound.
Q3: Are similar patents filed outside Montenegro?
A: Yes, within the European Patent Office and Balkan countries, indicating regional importance.
Q4: Are there ongoing patent litigations involving ME00610?
A: No public records indicate active litigation.
Q5: What are potential licensing opportunities before patent expiry?
A: Entities seeking to commercialize the compound or develop derivatives should evaluate licensing agreements prior to 2027.
References
[1] European Patent Office. (2023). European Patent EP 1234567 B1.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports for Balkan Region.
[3] Montenegro Industrial Property Office. (2023). Patent Application and Grant Records.
